Page 57 - Read Online

Page 10 of 12 Armstrong et al. Hepatoma Res 2021;7:18 I http://dx.doi.org/10.20517/2394-5079.2020.118

2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30.
3. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology
2004;127:S35-50.
4. Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 2013;47 Suppl:S2-6.
5. Fitzmorris P, Singal AK. Surveillance and Diagnosis of Hepatocellular Carcinoma. Gastroenterol Hepatol (N Y) 2015;11:38-46.
6. Kudo M. Japan’s Successful Model of Nationwide Hepatocellular Carcinoma Surveillance Highlighting the Urgent Need for Global
Surveillance. Liver Cancer 2012;1:141-3.
7. Vitale A, Peck-Radosavljevic M, Giannini EG, et al. Personalized treatment of patients with very early hepatocellular carcinoma. J
Hepatol 2017;66:412-23.
8. Santambrogio R, Kluger MD, Costa M, et al. Hepatic resection for hepatocellular carcinoma in patients with Child-Pugh’s A cirrhosis: is
clinical evidence of portal hypertension a contraindication? HPB (Oxford) 2013;15:78-84.
9. Xu DW, Wan P, Xia Q. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: A review. World J Gastroenterol
2016;22:3325-34.
10. Ye SL, Takayama T, Geschwind J, Marrero JA, Bronowicki JP. Current approaches to the treatment of early hepatocellular carcinoma.
Oncologist 2010;15 Suppl 4:34-41.
11. Burak KW. Prognosis in the early stages of hepatocellular carcinoma: Predicting outcomes and properly selecting patients for curative
options. Can J Gastroenterol 2011;25:482-4.
12. Byam J, Renz J, Millis JM. Liver transplantation for hepatocellular carcinoma. Hepatobiliary surgery and nutrition 2013;2:22-30.
Hepatobiliary Surg Nutr 2013;2:22-30.
13. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with
cirrhosis. N Engl J Med 1996;334:693-9.
14. Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma. Semin Intervent Radiol 2013;30:3-11.
15. Yamakado K, Takaki H, Nakatsuka A, et al. Radiofrequency ablation for hepatocellular carcinoma. Gastrointest Interv 2014;3:35-39.
16. Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med 2008;359:378-90.
17. Cheng A, Kang Y, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular
carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncology 2009;10:25-34.
18. Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J
Med 2018;379:54-63.
19. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE):
a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.
20. Finn RS, Qin S, Ikeda M, et al; IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N
Engl J Med 2020;382:1894-905.
21. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:
a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73.
22. Yau T, Kang Y, Kim T, et al. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular
carcinoma (aHCC): Results from CheckMate 040. JCO 2019;37:4012.
23. Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib
(KEYNOTE-224): a non-randomised, open-label phase 2 trial. The Lancet Oncology 2018;19:940-52.
24. Zhu AX, Park JO, Ryoo B, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular
carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. The Lancet
Oncology 2015;16:859-70.
25. Iwanaga T. Studies on cases of spontaneous regression of cancer in Japan in 2011, and of hepatic carcinoma, lung cancer and pulmonary
metastases in the world between 2006 and 2011. Gan To Kagaku Ryoho 2013;40:1475-87.
26. Kumar A, Le DT. Hepatocellular Carcinoma Regression After Cessation of Immunosuppressive Therapy. J Clin Oncol 2016;34:e90-2.
27. Parks AL, McWhirter RM, Evason K, Kelley RK. Cases of spontaneous tumor regression in hepatobiliary cancers: implications for
immunotherapy? J Gastrointest Cancer 2015;46:161-5.
28. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature 2017;541:321-30.
29. Kim JY, Kronbichler A, Eisenhut M, et al. Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic
Review and Meta-Analysis. Cancers (Basel) 2019;11:1798.
30. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/
Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 2020;38:1-10.
31. Stenzinger A, Allen JD, Maas J, et al. Tumor mutational burden standardization initiatives: Recommendations for consistent tumor
mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. Genes Chromosomes Cancer
2019;58:578-88.
32. Subrahmanyam PB, Dong Z, Gusenleitner D, et al. Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1
immunotherapy in melanoma patients. J Immunother Cancer 2018;6:18.
33. Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med 2016;14:73.
34. Vinay DS, Ryan EP, Pawelec G, et al. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol
2015;35 Suppl:S185-98.